Sphingosine-1-phosphate as a mediator of high-density lipoprotein effects in cardiovascular protection

被引:139
作者
Sattler, Katherine [1 ]
Levkau, Bodo [1 ]
机构
[1] Univ Klinikum Essen, Inst Pathophysiol, Zentrum Innere Med, D-45122 Essen, Germany
关键词
High-density lipoproteins (HDL); Sphingosine-1-phosphate (S1P); Cardiovascular protection; ENDOTHELIAL NITRIC-OXIDE; NECROSIS-FACTOR-ALPHA; SMOOTH-MUSCLE-CELLS; SPHINGOSINE 1-PHOSPHATE RECEPTORS; ADHESION MOLECULE EXPRESSION; A-I-MILANO; ISCHEMIA-REPERFUSION INJURY; REVERSE CHOLESTEROL TRANSPORT; RANDOMIZED CONTROLLED-TRIAL; LEFT-VENTRICULAR FUNCTION;
D O I
10.1093/cvr/cvp070
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Sphingosine-1-phosphate (S1P) has gained special attention in the high-density lipoprotein (HDL) field because HDL is the most prominent plasma carrier of S1P and because the S1P content of HDL may be responsible for many of the pleiotropic functions of HDL. This revelation has come from the evidence that HDL employ S1P receptors and signalling pathways to implement several HDL-ascribed biological effects as diverse as endothelial nitric oxide production, vasodilation, survival, and cardioprotection. This review focuses on HDL effects that are completely or partially mediated by the S1P content of the HDL particle and differentiates them from genuine HDL effects that are S1P-independent. In addition, the functional properties of 'free', HDL-unbound S1P are sometimes different from or even contrary to those of HDL-associated S1P. The nature of the physical interactions between HDL and local and systemic S1P production will be discussed as well as their consequences for organ function. Finally, we will elucidate the potential benefits and limitations of S1P analogues as a new class of functional HDL mimetics for cardiovascular therapy.
引用
收藏
页码:201 / 211
页数:11
相关论文
共 172 条
[1]   Sphingolipid signalling in the cardiovascular system: Good, bad or both? [J].
Alewijnse, Astrid E. ;
Peters, Stephan L. M. .
EUROPEAN JOURNAL OF PHARMACOLOGY, 2008, 585 (2-3) :292-302
[2]   The paradox of dysfunctional high-density lipoprotein [J].
Ansell, Benjamin J. ;
Fonarow, Gregg C. ;
Fogelman, Alan M. .
CURRENT OPINION IN LIPIDOLOGY, 2007, 18 (04) :427-434
[3]   Inflammatory/antiinflammatory properties of high-density lipoprotein distinguish patients from control subjects better than high-density lipoprotein cholesterol levels and are favorably affected by simvastatin treatment [J].
Ansell, BJ ;
Navab, M ;
Hama, S ;
Kamranpour, N ;
Fonarow, G ;
Hough, G ;
Rahmani, S ;
Mottahedeh, R ;
Dave, R ;
Reddy, ST ;
Fogelman, AM .
CIRCULATION, 2003, 108 (22) :2751-2756
[4]   High density lipoprotein-associated sphingosine 1-phosphate promotes endothelial barrier function [J].
Argraves, Kelley M. ;
Gazzolo, Patrick J. ;
Groh, Eric M. ;
Wilkerson, Brent A. ;
Matsuura, Bryan S. ;
Twal, Waleed O. ;
Hammad, Samar M. ;
Argraves, W. Scott .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2008, 283 (36) :25074-25081
[5]   Cholesterol binding, efflux, and a PDZ-interacting domain of scavenger receptor-BI mediate HDL-initiated signaling [J].
Assanasen, C ;
Mineo, C ;
Seetharam, D ;
Yuhanna, IS ;
Marcel, YL ;
Connelly, MA ;
Williams, DL ;
de la Llera-Moya, M ;
Shaul, PW ;
Silver, DL .
JOURNAL OF CLINICAL INVESTIGATION, 2005, 115 (04) :969-977
[6]   High-density lipoprotein cholesterol as a predictor of coronary heart disease risk. The PROCAM experience and pathophysiological implications for reverse cholesterol transport [J].
Assmann, G ;
Schulte, H ;
vonEckardstein, A ;
Huang, YD .
ATHEROSCLEROSIS, 1996, 124 :S11-S20
[7]  
Aviram M, 1996, EUR J CLIN CHEM CLIN, V34, P599
[8]  
BARR DP, 1951, AM J MED, V11, P480, DOI 10.1016/0002-9343(51)90183-0
[9]   HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events [J].
Barter, Philip ;
Gotto, Antonio M. ;
LaRosa, John C. ;
Maroni, Jaman ;
Szarek, Michael ;
Grundy, Scott M. ;
Kastelein, John J. P. ;
Bittner, Vera ;
Fruchart, Jean-Charles .
NEW ENGLAND JOURNAL OF MEDICINE, 2007, 357 (13) :1301-1310
[10]   New insights into the role of HDL as an anti-inflammatory agent in the prevention of cardiovascular disease [J].
Barter P.J. ;
Puranik R. ;
Rye K.-A. .
Current Cardiology Reports, 2007, 9 (6) :493-498